Patents by Inventor Marito ARAKI

Marito ARAKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CLEAVED MUTANT CALR-CD3 BISPECIFIC ANTIBODY AND PHARMACEUTICAL COMPOSITION
    Publication number: 20240092890
    Abstract: A bispecific antibody including a first domain which specifically binds to a mutant calreticulin protein and a second domain which specifically binds to a CD3 antigen. A pharmaceutical composition including the bispecific antibody or a functional fragment thereof. A diagnostic method for a myeloproliferative neoplasm, including detecting a polypeptide in a biological sample with the bispecific antibody.
    Type: Application
    Filed: August 26, 2021
    Publication date: March 21, 2024
    Applicants: JUNTENDO EDUCATIONAL FOUNDATION, MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Norio KOMATSU, Marito ARAKI, Yoshihiko KIHARA, Yoji ISHIDA, Koichi KITAMURA, Takayoshi FUKUSHIMA, Kaori YASUI
  • THERAPEUTIC DRUG FOR POLYCYTHEMIA
    Publication number: 20230220098
    Abstract: It is an object of the present invention to provide a therapeutic drug for polycythemia. According to the present invention, provided is a therapeutic drug for polycythemia, comprising an antibody which recognizes the amino acids at positions 629 to 633 of a human transferrin receptor.
    Type: Application
    Filed: September 4, 2020
    Publication date: July 13, 2023
    Applicants: PERSEUS PROTEOMICS INC., JUNTENDO EDUCATIONAL FOUNDATION
    Inventors: Lilin ZHANG, Fumiko NOMURA, Norio KOMATSU, Marito ARAKI
  • ANTIBODIES THAT BIND TO CLEAVED FORM OF MUTANT CALRETICULIN, AND DIAGNOSTIC, PREVENTIVE, OR THERAPEUTIC AGENT FOR MYELOPROLIFERATIVE NEOPLASM
    Publication number: 20220098290
    Abstract: A diagnostic, preventive, or therapeutic agent may be used for a myeloproliferative neoplasm. An antibody or a functional fragment thereof that binds to a cleaved mutant CALR protein, may include an antigen-recognition site in (a) a polypeptide chain having an amino acid sequence set forth in SEQ ID NO: 1 or (b) a polypeptide chain having an amino acid sequence having deletion, substitution, or addition of one to several amino acids in SEQ ID NO: 1; and a diagnostic, preventive, or therapeutic agent for a myeloproliferative neoplasm containing the antibody.
    Type: Application
    Filed: February 28, 2020
    Publication date: March 31, 2022
    Applicants: JUNTENDO EDUCATIONAL FOUNDATION, MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Marito ARAKI, Yoshihiko KIHARA, Norio KOMATSU